Document:

EX-10.1

 Exhibit 10.1 

First Amendment to License Agreement 

This First Amendment to License Agreement (this “First Amendment”), is made as of the 18th day of June, 2018, by and between
Cue Biopharma, Inc., a Delaware corporation having a place of business located at 675 W. Kendall Street, Cambridge, Massachusetts (“Licensee”) and MIL 21E, LLC, a Delaware limited liability company having a place of business located
at 675 West Kendall Street, Cambridge, MA 02142 (“Licensor”). 
 WITNESSETH: 

Reference is hereby made to the following facts: 

A.    Licensor and Licensee entered into that certain License Agreement (the “Existing License”),
dated as of January 9, 2018, for certain premises (the “Licensed Premises”) comprised of approximately 19,833 rentable square feet located on the first (1st) floor of the
building commonly known as 21 Erie Street, Cambridge, Massachusetts 02139 (as more particularly described in the Existing License, the “Building”), all as more particularly described in the Existing License. All capitalized words
and phrases not otherwise defined herein shall have the meanings ascribed to them in the Existing License. The Existing License, as modified and amended by this First Amendment, is referred to herein as the “License Agreement.” 

B.    Licensor and Licensee have agreed to modify and amend the Existing License, all in the manner hereinafter set forth.

 NOW THEREFORE, in consideration of Ten Dollars ($10.00) and other good and valuable consideration, the receipt, sufficiency and delivery
of which are hereby acknowledged, the parties agree that the License Agreement is hereby amended as follows: 

1.    Term and Termination. Article 2a. of the Existing License is hereby amended by deleting the Article 2a in its
entirety and replacing it with the following: 
 “Unless terminated earlier in accordance with this Section 2, the term
(“Term”) of this Agreement shall commence on May 15, 2018 (“Term Commencement Date”) and expire on April 14, 2021 (“Term Expiration”). Under no circumstance shall Licensor be liable to Licensee
for failure to deliver the Licensed Premises to Licensee in the Required Delivery Condition on or before May 15, 2018; provided, however, that if Licensor is unable to deliver the Licensed Premises to Licensee in the Required Delivery Condition
on or before May 15, 2018, the Term Commencement Date shall be delayed until the day on which Licensor delivers the Licensed Premises to Licensee in the Required Delivery Condition. For purposes of the preceding sentence, the term
“Required Delivery Condition” shall mean all improvements listed in Exhibit 2 of this License Agreement shall be completed, all services required for Licensee’s use and occupancy of the Licensed Premises for its intended use shall be
available and the entirety of the Licensed Premises shall otherwise be ready for Licensee’s use for its intended purpose. If the Term Commencement Date is delayed until after May 15, 2018, then Licensee shall receive

  
 1 

 
four (4) days abatement of the License Fee and all other charges payable by Licensee under this Agreement (collectively, the “Abatements”) for each day of such delay (collectively
the “Delay”). Licensee shall owe no License Fee or any other charges otherwise payable by Licensee under this Agreement for any days during the Delay in which Licensee does not have access to the Licensed Premises in the Required Delivery
Condition. Further, beginning with the License Fee and other amounts owed by Licensee for the nineteenth month of occupancy (and beyond as applicable), Licensee shall be entitled to credit all such Abatements against amounts owed by Licensee until
all such Abatements have been fully exhausted. 
 Notwithstanding the foregoing, Licensor and Licensee agree that Licensee is entitled to
five (5) days of abatement and therefore Licensor shall credit Licensee $42,145 in the nineteenth (19th) month of the Term of the License Agreement. Licensee shall not be entitled to any
additional Abatements or payments.” 
 2.    Moving Expenses. The final paragraph of Article 3 of the
Existing License is hereby deleted and replaced with the following: 
 “Licensee shall be entitled to a
one-time credit against Licensee’s obligation to pay the License Fee, to cover any and all reasonable moving, interim workspace and decontamination costs associated with Licensee’s relocation from
Licensor’s existing facility located at 675 West Kendall Street, Cambridge, Massachusetts to the Licensed Premises, including, without limitation, any such costs incurred in connection with Licensee’s occupancy of any interim space while
awaiting delivery of the Licensed Premises in the condition required hereunder. The foregoing costs, in the aggregate, shall not exceed $75,000. Licensee shall submit to Licensor all receipts, invoices and proofs of payment demonstrating
Licensee’s costs associated with the foregoing.” 
 3.    License Fee. 

The first sentence of Article 3 of the Existing License is hereby deleted and replaced with the following: 

“Licensee shall pay a license fee equal to Two Hundred Ninety Seven Thousand Four Hundred Ninety Five Dollars ($297,495.00) per month for
the first eighteen (18) months of the Term and shall pay a license fee equal to Three Hundred Thirty Thousand Five Hundred Fifty Dollars ($330,550.00) per month for the remainder of the Term (“License Fee”), which shall be paid
in advance on or before the first day of each and every month during the Term.” 
 The following shall be added to the third paragraph of Article 3:

 Provided that, on or before June 7, 2018, Licensee prepays the License Fee for the first seven and
one-half (7.5) months of the Term (“License Fee Prepayment”), the monthly License Fee for the first seven and one-half (7.5) months of the Term shall be
reduced from $297,495.00 to $252,870.00. Licensor acknowledges that Licensee has already paid $297,495.00 toward the License Fee Prepayment and therefore Licensee shall pay the remainder, $1,599,030.00, on or before June 7, 2018. 

  
 2 

 4.     Wet Lab Benches. The first row, third column of Exhibit 2 of
the Existing License is hereby deleted and replaced with the following: 
  

			
	Laboratory Space	  	 Laboratory suites
that vary in size from 500 – 18,000 sqft and in configurations of either Chemistry, Molecular Biology (BSL 1 and 2), or a mix of the two. Suites may include private offices. Laboratories can be equipped with certified fume hoods, central gas
lines for CO2 and Nitrogen, reverse osmosis deionized water, and heavy electrical and exhaust infrastructure.
  

Other gases and chemicals provided:
  

1.  Vacuum

2.  Compressed Air (medical grade)

3.  Dry ice

4.  Liquid Nitrogen

5.  Others by special order
  

Equipment provided shall include:
  

1.  Private BSL 40 wet lab benches, sink, eye-wash and safety
shower.
 2.  Private BSL2 cell/tissue culture room

3.  Optional Private Chemistry hood with solvent storage

4.  In-Lab Refrigerator/Freezer (Innovation Suites)

5.  In-Lab Centrifuge and Microfuge and Vortexer (Innovation
Suites)
 6.  In-Lab Waterbath (Innovation Suites)

7.  In-Lab Pipettes and Racks (Innovation Suites)

8.  In-Lab Microscope (Innovation Suites)

9.  Shared access to Shared Equipment (see list following)

 
 Licensee will need to assign a Laboratory Supervisor, i.e. EHS contact person, for each
laboratory occupied by the Licensee.

 5.    Ratification. As hereby amended, the License Agreement is ratified, approved
and confirmed in all respects. In the event that any of the provisions of the License Agreement are inconsistent with this First Amendment or the state of facts contemplated hereby, the provisions of this First Amendment shall control. 

(signatures on following page) 

  
 3 

 IN WITNESS WHEREOF, Licensor and Licensee have duly executed this First Amendment as of
the day and year first above written. 
  

					
	LICENSOR:	 		 	LICENSEE:
			
	MIL 21E, LLC	 		 	CUE BIOPHARMA, INC.
			
	 /s/ Seth Taylor
	 		 	 /s/ Daniel Passeri

	By: Seth Taylor	 		 	By: Daniel Passeri
	Title: CEO and CBO	 		 	Title: President and CEO

  
 4Exhibit 10.1

 

June 20, 2018

 

STRICTLY CONFIDENTIAL

 

Trinity Place Holdings Inc.

340 Madison Avenue, Suite 3C

New York, New York 10173

Attention: Steven Kahn, Chief Financial
Officer

 

Dear Mr. Kahn:

 

This letter (the “Amendment”)
constitutes an agreement between Trinity Place Holdings Inc. (the “Company”) and Craig-Hallum Capital Group
LLC (the “Manager”) to amend the At The Market Offering Agreement, dated as of December 2, 2016, between the
Company and the Manager (the “ATM Agreement”) as set forth herein. Defined terms that are used but not defined
herein shall have the meanings ascribed to such terms in the ATM Agreement.

 

1.      The
defined term “Agreement” in the ATM Agreement is amended to mean the Agreement as amended by this Amendment.

 

2.     
Section 2(b)(i) of the ATM Agreement is hereby amended and restated as follows:

 

“The Shares are to be sold on a daily
basis or otherwise as shall be agreed to by the Company and the Manager on any day that (A) is a trading day for the Trading
Market, (B) the Company has instructed the Manager by telephone (confirmed promptly by electronic mail) to make such sales
(“Sales Notice”) and (C) the Company has satisfied its obligations under Section 6 of this Agreement. The Company
will designate the maximum amount of the Shares to be sold by the Manager daily (subject to the limitations set forth in Section
2(d)) and the minimum price per Share at which such Shares may be sold. Subject to the terms and conditions hereof, the Manager
shall use its commercially reasonable efforts to sell on a particular day all of the Shares designated for the sale by the Company
on such day. The gross sales price of the Shares sold under this Section 2(b) shall be the market price for shares of the
Company’s Common Stock sold by the Manager under this Section 2(b) on the Trading Market at the time of sale of such
Shares.”

 

3.     
Section 8(c) of the ATM Agreement is hereby amended and restated as follows:

 

“This Agreement shall remain in full
force and effect until the earlier of June 30, 2019 and such date that this Agreement is terminated pursuant to Sections 8(a)
or (b) above or otherwise by mutual agreement of the parties, subject to extension of the term by mutual written agreement
of the parties; provided that any such termination by mutual agreement shall in all cases be deemed to provide that Sections 5,
7, 8, 9, 10, 12, 14 and 15 shall remain in full force and effect.”

 

4.      The Company and the Manager hereby agree that the date of this Amendment shall be a Representation Date and the Company
shall make the deliveries required by Section 6 of the ATM Agreement, including, without limitation, the filing of a Prospectus
Supplement with the Commission, on the date hereof.

 

5.      In connection with this Amendment, the Company shall reimburse the Manager for the fees and expenses of the Manager’s
counsel in an amount not to exceed $50,000, which shall be paid on the date hereof.

 

6.      Except as expressly set forth herein, all of the terms and conditions of the ATM Agreement shall continue in full force
and effect after the execution of this Amendment and shall not be in any way changed, modified or superseded by the terms set forth
herein.

 

7.      This
Amendment may be executed in two or more counterparts and by facsimile or “.pdf” signature or otherwise, and each
of such counterparts shall be deemed an original and all of such counterparts together shall constitute one and the same agreement.

 

 

[remainder of page
intentionally left blank]

 

     

     

    

 

 

In acknowledgment that
the foregoing correctly sets forth the understanding reached by the Company and the Manager, please sign in the space provided
below, whereupon this Amendment shall constitute a binding amendment to the ATM Agreement as of the date indicated above.

 

 

 

	 	Very truly
yours,
	 	 	 
	 	CRAIG-HALLUM
CAPITAL GROUP LLC
	 	 	 
	 	By:	/s/ Rick Hartfiel
	 	Name:	Rick Hartfiel
	 	Title:	Head of Investment
Banking

 

	Accepted and Agreed:	 
	 	 	 
	TRINITY PLACE HOLDINGS INC.	 
	 	 	 
	By:	/s/ Steven Kahn	 
	Name:	Steven Kahn	 
	Title:	Chief Financial Officer	 

 

  

[signature
page to TPHS Amendment to atm agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]